Reported 2 days ago
Eli Lilly is a notable player in the pharmaceutical sector, but its stock outlook is mixed due to the potential impact of President Trump's tariffs, which could increase costs and pressure profit margins. Despite these short-term uncertainties, the company has promising long-term prospects, bolstered by successful products like Mounjaro and Zepbound, and opportunities in cancer and Alzheimer's medications. For investors with a long-term view, this might be a good time to consider Eli Lilly stock, albeit with a dollar-cost averaging strategy to manage risk.
Source: YAHOO